CuraGen Corporation has omitted from this Exhibit 10.11 portions of the Agreement for which CuraGen Corporation has requested confidential treatment from the Securities and Exchange Commission. The portions of the Agreement for which confidential...
Option and Exclusive License Agreement • March 17th, 1998 • Curagen Corp • Services-commercial physical & biological research
Contract Type
Filed
March 17th, 1998
Company
Industry

Contract
Option and Exclusive License Agreement • November 18th, 2019
Contract Type
Filed
November 18th, 2019
DEBIOPHARM AND AURIGENE SIGN AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALISATION OF DEBIO 1142, A NOVEL INHIBITOR OF AN UNDISCLOSED ONCOLOGY PATHWAY

Option and Exclusive License Agreement Sample Contracts

Filter & Search